Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 270

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 270
---
 the terms of our amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering, we will divide our board of directors into three classes, Class I, Class II, and Class III, with members of each class serving a staggered three-year term. In connection with this offering, our board of directors will be divided into the following three classes:

| • |     | Class I, which will consist of Zachary Prensky, Rebecca Luse, and Ran Nussbaum, whose terms will expire at 
 our annual meeting of stockholders to be held in 2026;                                                     |

| • |     | Class II, which will consist of Robert R. Ruffolo, Jr., Scott Garland, and Heather Turner, whose terms will 
 expire at our annual meeting of stockholders to be held in 2027; and                                        |

| • |     | Class III, which will consist of Rekha Hemrajani and William Kane, whose terms will expire at our annual 
 meeting of stockholders to be held in 2028.                                                              |

At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. Our amended and restated bylaws that will become effective immediately prior to the closing of this offering will provide that the authorized number of directors may be changed only by resolution of a majority of our board of directors. Any additional directorships resulting from an increase in the number of directors or from the filling of any current vacancies will be distributed between the three classes so that, as nearly as possible, each class will consist of one-third ofthe directors. This classification of our board of directors may have the effect of delaying or preventing changes in our control or management. Director Independence Our board of directors has undertaken a review of the independence of our directors and considered whether any director has a relationship that, in the opinion of the board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a member of our board. Based upon information requested from and provided by each director concerning such director’s background, employment, and affiliations, including family relationships, our board of directors has determined that all of our directors, except 183

for Ms. Turner and Mr. Prensky, representing six of our eight directors, are “independent directors” as defined under the listing standards of Nasdaq. In making these
d